Key result
The hERG activator RPR260243 abbreviated action potential duration and increased refractoriness, rescuing induced ventricular arrhythmia in a zebrafish heart model.
Why the study?
hERG channel dysfunction causes long QT syndrome and arrhythmia, making activator compounds of interest for their therapeutic potential.
The hERG activator RPR260243 demonstrates antiarrhythmic potential by abbreviating action potential duration and increasing refractoriness in a zebrafish heart model.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating in zebrafish; leaves open translation of hERG activation to mammalian or human arrhythmia therapy.
hERG channel dysfunction causes long QT syndrome and arrhythmia. Activator compounds have been of significant interest due to their therapeutic potential. We used the whole organ zebrafish heart model to demonstrate the antiarrhythmic benefit of the hERG activator, RPR260243. The activator abbreviated APD and increased refractoriness, the combined effect of which rescued induced ventricular arrhythmia. Our findings show that the targeted slowing of hERG channel deactivation and enhancement of protective currents caused by the RPR260243 activator may provide an effective antiarrhythmic approach.
No takes yet. Share an insight, caveat, or question.
Shi et al. (2020) studied Ventricular arrhythmia. RPR260243 was evaluated on Action potential duration (APD), refractoriness, and induced ventricular arrhythmia. The hERG activator RPR260243 abbreviated action potential duration and increased refractoriness, rescuing induced ventricular arrhythmia in a zebrafish heart model.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: